1) Today’s News Headlines
The FDA is escalating its crackdown on telehealth marketing of compounded “GLP-1” products, issuing warning letters to 30 companies for allegedly false or misleading claims. (fda.gov)
At the same time, Novo Nordisk and Hims & Hers struck a deal to sell branded Ozempic and Wegovy on Hims’ platform—ending a lawsuit and signaling the “$199 copycat” era may be tightening fast. (apnews.com)
Plus: a new Phase 2 trial in Nature Medicine suggests it may be possible to “uncouple” fat loss from muscle loss—one of the biggest fears in modern weight-loss treatment. (nature.com)
2) Today’s Top Stories (past 24 hours)
Novo Nordisk + Hims & Hers: From Legal Fight to Branded GLP-1 Access
Novo Nordisk is dismissing its patent lawsuit against Hims & Hers as the companies move into a collaboration that will allow Hims to offer branded Ozempic and Wegovy (injectable and oral forms) through its telehealth platform. Reports note Hims had previously floated an “off-brand” version and then backed off amid regulatory pressure. (apnews.com)
Why it matters: If you’ve relied on compounded semaglutide for price or access, this is another sign the market is shifting toward regulated, branded channels—likely affecting cost and continuity.
Source: Associated Press (apnews.com)
FDA Issues Warning Letters to 30 Telehealth Companies Over Compounded GLP-1 Marketing
The FDA announced it issued 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products offered on their websites. This is part of a broader push against illegal promotion and potentially unsafe or inaccurately represented compounded products. (fda.gov)
Why it matters: Compounded meds can be appropriate in limited situations, but marketing them like interchangeable “Wegovy/Ozempic” clones can expose patients to quality, dosing, and safety risks.
Source: FDA (Press Announcement, March 3, 2026) (fda.gov)
Amazon Pharmacy Expands to Zepbound KwikPen (Same-Day Delivery in Some Areas)
Amazon Pharmacy is expanding its GLP-1 offering to include Eli Lilly’s Zepbound KwikPen, with reports citing same-day delivery availability in certain locations. (seekingalpha.com)
Why it matters: Access and logistics (not just prescriptions) can make or break adherence—especially for injectable therapies that people need reliably month after month.
Source: Seeking Alpha (seekingalpha.com)
New Phase 2 Trial: Bimagrumab + Semaglutide and the “Muscle-Loss Problem”
A randomized Phase 2 trial in Nature Medicine evaluated semaglutide alone, bimagrumab alone, and combinations, with findings supporting the idea that it may be feasible to reduce fat mass while better preserving (or improving) lean mass outcomes during weight reduction. (nature.com)
Why it matters: Many people lose not only fat but also muscle during weight loss; approaches that protect lean mass could improve metabolic health, function, and long-term maintenance.
Source: Nature Medicine (Published March 2, 2026) (nature.com)
3) Deep Dive (Tuesday — Science Simplified)
The Big Question: “Can I lose weight without losing muscle?”
Why this matters: Muscle isn’t just “for looks.” It supports resting metabolic rate, strength, balance, glucose regulation, and long-term weight maintenance. Rapid weight loss—whether from aggressive dieting or medication—often includes some lean mass loss.
What the new study looked at (in plain English):
The Nature Medicine Phase 2 trial tested adults with obesity (without diabetes) across multiple groups receiving placebo, semaglutide (including 2.4 mg weekly), bimagrumab (an IV medication studied for body composition effects), and combinations for 48 weeks. (nature.com)
The authors report evidence that “uncoupling” fat loss from lean mass loss may be feasible—meaning future obesity treatments might deliver more fat loss with less muscle loss than we typically see with weight reduction. (nature.com)
What you should do with this information today (actionable, no hype):
- Make protein a daily anchor—especially if appetite is low on GLP-1s.
Many GLP-1 users unintentionally undereat protein because portions shrink. A practical target many clinicians use is spreading protein across meals (e.g., 25–40g per meal depending on body size, goals, and medical history). If you struggle: start by adding one “protein-first” food at breakfast. - Strength train 2–3x/week (even brief sessions count).
You don’t need perfect programming: consistent resistance work signals your body to keep muscle during weight loss. Think: squat/hinge/push/pull/carry patterns. - Avoid the “scale-only” trap.
If you’re losing weight fast but feeling weaker, colder, more fatigued, or noticing hair shedding—those can be clues you’re under-fueling. Consider tracking waist, strength, and energy alongside weight. - Myth-bust (kindly): “GLP-1s melt fat without effort.”
Medications can be powerful tools, but body composition outcomes still depend heavily on protein intake, resistance training, sleep, and total nutrition quality. The science is moving toward better meds and better lifestyle pairing—not replacing one with the other. (nature.com)
Safety note: If you’re on a GLP-1 medication and struggling to eat enough (nausea, early fullness, food aversions), talk to your prescriber—dose timing, titration pace, side-effect management, and nutrition strategies can often help.
4) Quick Hits
- If you’re seeing “compounded GLP-1” ads that sound identical to Ozempic/Wegovy, note the FDA says it’s targeting misleading claims by telehealth companies. (fda.gov)
- The Novo Nordisk–Hims shift is a real-time example of how access channels are changing (branded partnerships rising; copycat marketing shrinking). (statnews.com)
- Muscle-preserving obesity pharmacotherapy is becoming a major research theme—expect more combination trials like the Nature Medicine study. (nature.com)
- If you use Amazon Pharmacy, Zepbound KwikPen availability may improve fulfillment convenience in select areas. (seekingalpha.com)
- Reminder: stopping GLP-1s often leads to regain for many people; ongoing support plans matter (nutrition, activity, behavior, and/or step-down medical strategies). (ox.ac.uk)
- Policy watch: PAHO/WHO has urged strengthened pharmacovigilance amid reports of GLP-1 misuse—an indicator that regulators globally are paying closer attention. (paho.org)
5) By The Numbers
30 = the number of warning letters the FDA says it issued to telehealth companies over allegedly false or misleading marketing of compounded GLP-1 products. (fda.gov)
What it means: Enforcement is no longer theoretical—regulators are actively pressuring the marketplace.
Why you should care: If your care plan relies on compounded GLP-1s, you may want a “continuity plan” (coverage options, branded access pathways, and a clinically supervised transition strategy if needed).
Source: FDA (March 3, 2026) (fda.gov)
6) Ask The Community
If appetite suppression makes it hard to eat “enough” (protein, fiber, overall calories), what’s one food or routine that reliably helps you stay nourished without triggering nausea or feeling overly full?
7) Tomorrow’s Preview
Community Voices: a real-world maintenance strategy from Reddit—what worked, what didn’t, and how they handled plateaus without spiraling into restriction.